Botulinum Toxin Fragment Assembly via Disulfide Linker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing botulinum toxin face challenges such as high complexity, low safety, and economic feasibility due to the difficulty in expressing and assembling the light and heavy chains of botulinum toxin, which are essential for forming the full-length toxin, and the need for additional purification processes and safety equipment.
Innovation Solution
A method involving the production of botulinum toxin fragments using a plasmid and host cells, where the fragments are separately expressed and purified, and then assembled into full-length toxin through disulfide bond formation, utilizing protein trans-splicing to overcome the challenges of conventional production methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional methods are used to produce full-length botulinum toxin, then the toxin can be obtained, but the production process is complex and requires additional purification processes
Solution Approach 1:
The botulinum toxin is divided into separate functional domains (light chain and heavy chain) that are produced independently in different host cells. The light chain is produced in one host cell and the heavy chain in another, then assembled in vitro. This segmentation simplifies the overall production process by allowing parallel production and eliminating the need for complex in vivo assembly mechanisms.
Solution Approach 2:
A linker molecule serves as an intermediary to facilitate the assembly of the light chain and heavy chain into the full-length toxin. The linker contains a disulfide bond that mediates the formation of the interchain disulfide bond between the light and heavy chains, simplifying the assembly process without requiring complex cellular machinery.
2Reliability
If conventional production methods are used, then botulinum toxin can be produced, but safety risks increase due to the need for specialized safety equipment
Solution Approach 1:
By producing the toxin fragments in separate host cells using standard recombinant DNA technology, the production process can be conducted in ordinary laboratory settings rather than requiring specialized containment facilities. The separation of production steps reduces the risk of accidental toxin release while maintaining product integrity.
3Loss of time
If light and heavy chains are produced separately and assembled, then production time is reduced, but additional purification processes are required
Solution Approach 1:
The linker molecule acts as a built-in purification handle, allowing the assembled toxin to be selectively bound and purified using affinity chromatography. This eliminates the need for multiple sequential purification steps and simplifies the manufacturing process while maintaining the time advantages of separate production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces production time, improves the yield of soluble toxin, and allows for safer and more economical production of botulinum toxin, enabling its use in pharmaceutical applications while minimizing environmental and safety risks.
Implementation Method 1
assembled into full-length toxin through disulfide bond formation
Data Source
AI summary
The present invention relates to a method for producing botulinum toxin in various fragments to then be reassembled, for safely producing same. In the present invention, devised is a method in which: botulinum toxin is produced in fragments by cleaving light and heavy chains thereof into two or three pieces, respectively, and then combined as a full-length toxin, thereby allowing high complexity in production, due to toxicity, as well as low safety and economic feasibility, to be overcome; production of water-soluble botulinum toxin is enabled by using bacteria, thereby markedly shortening the production time as compared to existing production methods; and conjugation of the produced fragments with other proteins and nanoparticles is also enabled, thereby increasing the pharmaceutical extensibility of the toxin.